

To: jeffrey E. <jeevacation@gmail.com>
From: Boris Nikolic <[REDACTED]>
Subject: RE:
Sent: Wednesday, December 30, 2015 3:08:03 AM

I was talking to many people.

Just to give you a market comparable - for three leading gene editing company - editas, intellia and crispr TX - series A premoney was 5-10Mm.

These company have all fields of use versus egenesis has only xenotransplantation. So it should me lower valuation at series A premoney.
Also the risk I much greater.

I think that 5MM would be fair.
I would go to 7MM.
I would consider even super stretch at 10 but 27MM is totally crazy.
I told this to them - and George was on a phone.

Even more serious problem is that they do not realize how inexperienced they are.

Will tell you more tmr

B

Sent from my Windows Phone

From: [jeffrey E.](#)
Sent: 12/29/2015 7:10 PM
To: [Boris Nikolic](#)
Subject:

george is asking for his money at a 27 m valuation. what would you lke me to do

--

please note

The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE

Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to jeevacation@gmail.com, and destroy this communication and all copies thereof,

including all attachments. copyright -all rights reserved